Correction: Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial.

Clinical Cancer Research · 2 Nov 2026 · Published Erratum · Open access

Zinner, Mastrolonardo + more

The abstract is read at the publisher; the summary is JClub's.

There's no AI summary of this paper here yet.

Open access

Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.

Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial.
Clinical Cancer Research · 2 Nov 2026 · Clinical Trial, Phase II
AI summary · may contain errors
Neoadjuvant nivolumab plus carboplatin and paclitaxel in stage III–IV HPV-negative SCCHN and stage II–III HPV-positive oropharyngeal SCCHN achieved a 45% primary-site pCR.
- Open access
- 10 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41385730
Open in JClub
Neoadjuvant Chemoimmunotherapy Improves Response Rates in Head and Neck Cancer.
Clinical Cancer Research · 2 Nov 2026 · Journal Article
AI summary · may contain errors
Neoadjuvant nivolumab plus carboplatin and paclitaxel in locally advanced, resectable head and neck squamous cell carcinoma improves pathologic response rates versus chemotherapy or immunotherapy alone.
- 1 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/41842604
Open in JClub

Journals this month

All journals →

Topics moving, week to 13 Nov 2026

All topics →

By field

All journals by field →

Correction: Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial.

Related in JClub

Neoadjuvant Nivolumab plus Carboplatin and Paclitaxel in Patients with Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck: A Phase II, Single-Arm Trial.

Neoadjuvant Chemoimmunotherapy Improves Response Rates in Head and Neck Cancer.

Browse JClub